China Sinopharm’s vaccine has 79.34% protection rate against COVID-19


A COVID-19 vaccine developed by a Beijing firm linked to Sinopharm has a protection rate of 79.34% against the disease, the firm said in a statement on Wednesday.

Beijing Biological Products Institute Co. Ltd said it has applied to the National Medical Products Administration for the conditional approval of the vaccine.

The result is based on an interim analysis of data from the Phase III clinical trial, but the firm did not provide details such as the number of infections in the trial.

Leave a Reply